期刊文献+

老年2型糖尿病发生骨质疏松的临床多因素分析 被引量:8

Clinical multivariate analysis of osteoporosis in elderly patients with type 2 diabetes
下载PDF
导出
摘要 目的探讨老年2型糖尿病(T2DM)患者发生骨质疏松的影响因素。方法根据患者的骨密度值将患者分为骨量正常(NOP)组、低骨量(LBMD)组、骨质疏松(OP)组,对比3组在年龄、糖尿病病程、体质量指数(BMI)、胱抑素C(CysC)、经皮氧分压检查(TcPO2)、糖化血红蛋白(HbA1c)、尿C肽(U-CP)等指标之间的差异,并进行相关性分析。结果 (1)与NOP组相比,LBMD及OP组年龄、病程显著性升高,U-CP显著性下降;(2)OP组BMI、CysC显著低于NOP组;(3)OP组年龄显著高于LBMD组,而BMI显著低于LBMD组(P<0.05或P<0.01)。老年T2DM患者的BMD与年龄、病程呈负相关,与BMI、U-CP呈正相关。逐步多元回归分析显示U-CP是BMD的正性预测因子。结论老年T2DM患者并发骨质疏松与多因素有关,包括高龄、低体质量、病程长、胰岛功能差等。 Objective To investigate the influencing factors of osteoporosis in elderly patients with type 2 diabetes(T2DM).Methods 298 patients with T2DM were divided into 3 groups(according to their bone mineral density):normal bone mineral density(NOP) group,low bone mineral density(LBMD) group,osteoprosis(OP) group.Age,diabetes duration,body mass index(BMI),Cystatin C(Cys C),transcutaneous tissue oxygen tension(TcPO2),glycosylated hemoglobin(HbA1c),urinary C-peptide(U-CP) were compared among three groups.The correlation analysis was used to analyze the factors of OP.Results Compared with NOP group,patients in LBMD and OP group had older age,longer diabetic course,lower U-CP.BMI,Cys C level of patients in OP group were lower than those in NOP group,while the difference in age,BMI was statistically significant between OP and LBMD group(P0.01 or P0.05).BMD in elderly patients with T2DM was negatively correlated with age,disease course,but positively correlated with BMI and U-CP.Meanwhile,BMD was independently correlated with U-CP.Conclusions Osteoporosis in elderly patients with T2DM is related to a number of risk factors,including advanced age,low body weight,long-term history of diabetes,insulin dysfunction.
出处 《实用老年医学》 CAS 2012年第5期380-382,共3页 Practical Geriatrics
关键词 2型糖尿病 老年人 骨密度 骨质疏松 type 2 diabetes mellitus aged bone mineral density osteoporosis
  • 相关文献

参考文献10

  • 1冯缨缨,钟远,金俊.老年男性2型糖尿病合并骨质疏松症患者骨代谢生化指标分析[J].实用老年医学,2011,25(6):510-512. 被引量:10
  • 2Papioannou A, Kennedy CC, Ioannidis G, et al. The impact of incident fractures on health-related quality of life:5 years of data from the Canadian Muhicentre Osteoporosis Study [ J]. Osteoporos Int, 2009,20(5) :703-714.
  • 3金晖,蔡若男,何仕诚,邓钢.骨质疏松椎体骨折患者药物治疗现状调查[J].中华内分泌代谢杂志,2011,27(2):110-112. 被引量:15
  • 4Hamrick MW, Ferrari SL. Leptin and the sympathetic con- nection of fat to bone [ J ]. Osteoporos Int, 2008,19 (7) : 905-912.
  • 5Sugden JA, Davies JI, Witham MD, et al. Vitamin D im- proves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels[J]. Diabet Med,2008,25 ( 3 ) : 320-325.
  • 6Popov AA, Izmozherova NV, Tagil'tseva NV,et al. Metabo- lic syndrome and decreased bone mineral density in climac- teric women[J]. Kiln Med (Mosk) ,2008,86(9) :51-53.
  • 7Yamaguchi T, Sugimoto T. Calcium homeostasis and osteo- porosis in diabetes mellitus and the metabolic syndrome[ J ]. Clin Calcium, 2008,18 (7) :904-911.
  • 8Iwaniec UT, Dube MG, Boghossian S, et al. Body mass in- fluences cortical bone mass independent of leptin signaling [J]. Bone,2009,44(3):404-412.
  • 9Filler G, B6kenkamp A, Hofmann W, et al. Cystain C as a marker of GFR-history, indications, and future research [ J ]. Clin Bioehem,2005,38 ( 1 ) : 1-8.
  • 10Yamaguchi T, Kanazawa I, Yamamoto M, et al. Associa- tions between components of the metabolic syndrome versus bone mineral density and vertebral fracture in patients with type 2 diabetes [ J ]. Bone, 2009,45 ( 2 ) : 174-179.

二级参考文献22

  • 1薛延.老年骨质疏松患者骨代谢标志物的检测与应用[J].中华老年医学杂志,2006,25(6):410-413. 被引量:16
  • 2Papaioannou A,Kennedy CC,Ioannidis G,et al.The impact of incident fractures on health-related quality of life:5 years of data from the Canadian Multicentre Osteoporosis Study.Osteoporos Int,2009,20:703-714.
  • 3Bouxsein ML,Kaufman J,Tosi L,et al.Recommendations for optimal care of the fragility fracture patient to reduce the risk of future fracture.J Am Acad Orthop Surg,2004,12:385-395.
  • 4Kanis JA,on behalf of the World Health Organization Scientific Group.Assessment of osteoporosis at the primary health-care level.Technical Report,UK:WHO Collaborating Centre,University of Sheffield,2008.
  • 5Hajcsar EE,Hawker G,Bogoch ER.Investigation and treatment of osteoporosis in patients with fragility fractures.CMAJ,2000,163:819-822.
  • 6Shea B,Wells G,Graney A,et al.Calcium supplementation on bone loss in postmenopausal women.J Cochrane Database Syst Rev,2007,1:D004526.
  • 7Marcus R,Wong M,Heath H,et al.Antiresorptive treatment of postmenopausal osteoporosis:comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.Endocr Rev 2002;23:16-37.
  • 8Laurent C.Effects of osteoporosis medications on bone quality.Joint Bone Spine,2007,74:39-47.
  • 9Black DM,Cummings SR,Karpf DB,et al.Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.Fracture Intervention Trial Research Group.Lancet,1996,348:1535-1541.
  • 10Lufkin EG,Wong M,Deal C.The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.Rheum Dis Clin North Am,2001,27:163-185.

共引文献23

同被引文献50

引证文献8

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部